A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
BioNTech SE
BioNTech SE
Seagen Inc.
Bristol-Myers Squibb
Imunon
Tongji Hospital
Regeneron Pharmaceuticals
Parabilis Medicines, Inc.
NaviFUS Corporation
Astellas Pharma Inc
Genmab
CanariaBio Inc.
Tvardi Therapeutics, Incorporated
Alliance Foundation Trials, LLC.
Revolution Medicines, Inc.
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Tianjin Medical University Cancer Institute and Hospital
Shionogi Inc.
Lepu Biopharma Co., Ltd.
Hoffmann-La Roche
St. Jude Children's Research Hospital
Shanghai JMT-Bio Inc.
Immunocore Ltd
Qilu Pharmaceutical Co., Ltd.
MedImmune LLC
AstraZeneca
Neonc Technologies, Inc.
Roswell Park Cancer Institute
Mayo Clinic
Sun Yat-sen University
Luye Pharma Group Ltd.
FBD Biologics Limited
Bristol-Myers Squibb
AstraZeneca
AskGene Pharma, Inc.
The First Affiliated Hospital of Zhengzhou University
Sanofi
University of California, San Francisco
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Bristol-Myers Squibb
University of Birmingham
Gruppo Oncologico del Nord-Ovest
Adagene Inc
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Shanghai Hengrui Pharmaceutical Co., Ltd.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Bristol-Myers Squibb
Hoffmann-La Roche
Hoffmann-La Roche
University of Miami